Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

Table 4 Post-treatment prognostic factors for survival in hepatic arterial infusion chemotherapy treatment

Variables		Univariate	Multivariate1
		HR (95%CI)	Adjusted HR (95%CI)	P-value2
After 2nd HAIC cycle	Objective response
	Responder	1
	Non-responder	2.382 (0.995-5.704)
	Disease control
	Control group	1
	Progressive group	3.708 (1.801-7.634)	3.850 (1.768-8.381)	0.001
	PVTT response
	Response	1
	Non-response	2.531 (1.164-5.505)	3.398 (1.529-7.552)	0.003
	AFP reduction
	≥ 50%	1
	< 50%	3.242 (1.297-8.102)	3.031 (1.194-7.691)	0.02
	PIVKA-II reduction
	≥ 50%	1
	< 50%	3.164 (1.469-6.818)	2.254 (0.989-5.137)	0.053
Response during HAIC	Best tumor response
	Objective response
	Responder	1
	Non-responder	4.747 (2.111-10.672)	4.445 (1.893-10.439)	0.001
	Tumor control
	Control group	1
	Progressive group	3.274 (1.594-6.724)	3.137 (1.494-6.591)	0.003
	Intra-hepatic tumor response
	Objective response
	Responder	1
	Non-responder	4.747 (2.111-10.672)	4.445 (1.893-10.439)	0.001
	Tumor control
	Control group	1
	Progressive group	3.032 (1.348-6.821)	3.009 (1.302-6.958)	0.01
	PVTT response
	Response	1
	Non-response	9.587 (2.879-31.927)	8.188 (2.403-27.898)	0.001
	Combination therapy
	Yes	1
	No	2.367 (1.218-4.601)	2.164 (1.082-4.328)	0.029

¹Adjusted for tumor volume and pre-treatment PIVKA-II level;

²P value for adjusted hazard ratio. AFP: Alpha-fetoprotein; HAIC: Hepatic arterial infusion chemotherapy; PIVKA: Protein induced by vitamin K absence or antagonist; PVTT: Portal vein tumor thrombosis.